Bempedoic acid with ezetimibe is agreed for treating hypercholesterolaemia / mixed dyslipidaemia in line with NICE TA694 for patients in whom:

- statins are contraindicated or not tolerated (see Statin Intolerance pathway below)
- ezetimibe alone does not control low-density lipoprotein cholesterol well enough

Treatment should be initiated by a specilaist and the prescribing should remain with the specilaist for at least 3 months to ensure that the patient is responding to treatment before transfer of care to the patient's primary care prescriber.

NOTE: The combination preparation of bempedoic acid with ezetimibe is more cost effective than prescribing the separate components. However, it is appropriate to prescribe the bempedoic acid (single component) as an add-on in patients who have already started treatment with ezetimibe prior to the publication of this guidance.